The treatment is the first drug-accelerated treatment to be made available to cancer patients, a major milestone in a world-first effort to develop a cure.
The man, who has cancer, has been treated by Dr. Stephen Krasne at the University of British Columbia.
He was able, via a bone marrow transplant, to access the drug-acquired chemotherapy treatment in a hospital setting, said Dr. Michael Zuker, chief executive officer of the Canadian Cancer Society.
The treatment, called Angiogenesis, has proven effective in other patients with other types of cancer, and it is already being used in a pilot trial for people with other cancers, Zukar said.
Angiogenic is a drug that has been in clinical trials in the United States and Europe for nearly three years.
The drug is made by Novartis and is currently being studied for cancer treatments.
It is used to treat bone marrow tumors.
The U.S. Food and Drug Administration approved the drug in April, but Krasner is only testing it in patients with certain types of tumors, including melanoma, a type of skin cancer.
The Canadian Cancer Societies board approved the treatment last year, after it was proven to be safe and effective for the majority of patients.
“We’re extremely excited to be able to bring this important and groundbreaking treatment to the clinic,” Zukr said.
“This is a game-changer for cancer patients worldwide.”
The Angiogenys cancer-preventing drug was developed by the University and UBC’s Centre for Health Sciences.
The company has been granted $5.3 million in funding to help fund its development.
Angiopure, which is manufactured by Novatum and Pfizer, is used in the U.K., France, Germany, Denmark, the Netherlands, Spain and Sweden.
It was approved by the European Medicines Agency in July 2018.
The FDA approved it in March.
In the U, Angiopage was approved for treatment of Hodgkin’s lymphoma.
The United States approved it for treatment in January.
AngioPure was approved in April.
The new drug is being tested in a clinical trial at the British Columbia Centre for Human Genetics.
It has not been approved by any other country.
Krasnier said Angiogene has been tested in people with lung, liver, breast and colorectal cancers and in patients receiving chemotherapy for other types.
The patients who receive the treatment will be able begin taking it within six months.
The study is looking at whether the drug is safe and tolerable.
Patients who are receiving Angiophage, which costs $1,000 a dose, are given the drug to treat one type of cancer.
Patients can also take Angiologic to treat other types such as ovarian cancer, lymphoma and pancreatic cancer.
Kraan said Angiopile has been approved in the European Union and Canada, as well as by the U.-K.
The therapy was approved to treat Hodgkin lymphoma, melanoma and other types that can be treated with chemotherapy.
The European Union approved it as a treatment in 2015, and Canada approved it this year.
Angiospare, the U-K.-based drug company that is the lead manufacturer of Angiopare, said it is working with Novartes to find a partner for the clinical trial.
The trials are funded by the Ontario Health Plan and the Canada Cancer Foundation.
“While it is a first in Canada, this is an important milestone in the history of angiopure,” Zuiker said.
Kraker said the UBC clinical trial is expected to be completed by May 2021.
The trial will look at the effects of the drug on patients who have not been tested yet, such as people with rare, cancer-specific tumors.
Patients with the most severe types of the tumors can start taking the drug within five months, Krasnar said.
The disease will be monitored in the study over the next year or so, and then the company will decide whether to pursue further clinical trials.